Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS): A Rare but Potentially Treatable Condition

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2017 Apr 21

PMID 28424322

Citations 19

Authors

Michael Karass

Emily Grossniklaus

Talal Seoud

Sanjay Jain

Daniel A Goldstein

Affiliations

Soon will be listed here.

Abstract

Kaposi sarcoma inflammatory cytokine syndrome (KICS) is a newly-described condition affecting individuals who are HIV-positive and are infected with human herpesvirus 8 (HHV-8). This is a syndrome that in some ways mimics severe sepsis with associated acute respiratory distress syndrome, possibly requiring a ventilator and vasopressor support. However, unlike severe sepsis, antibiotics provide no benefit. Management of KICS has not been fully elucidated because of its high mortality rate. However, the syndrome has been successfully treated in some cases with immunomodulatory therapy. It is crucial for oncologists to be able to recognize this syndrome and to institute the appropriate therapy. 2017;22:623-625.

Citing Articles

Cardiac Kaposi Sarcoma Complicated by Kaposi Sarcoma Inflammatory Cytokine Syndrome: A Case Report.

Dagher A, Lee J, Cunningham H, Weiss J, Yarrington M Cureus. 2025; 17(1):e76972.

PMID: 39912008 PMC: 11794192. DOI: 10.7759/cureus.76972.

The Role of vIL-6 in KSHV-Mediated Immune Evasion and Tumorigenesis.

Komaki S, Inagaki T, Kumar A, Izumiya Y Viruses. 2025; 16(12.

PMID: 39772207 PMC: 11680145. DOI: 10.3390/v16121900.

Diagnosis and Management of Kaposi Sarcoma-Associated Herpesvirus Inflammatory Cytokine Syndrome in Resource-Constrained Settings: A Case Report and an Adapted Case Definition.

Kumwenda T, Hodson D, Rambiki K, Rambiki E, Fedoriw Y, Tymchuk C Trop Med Infect Dis. 2024; 9(12).

PMID: 39728834 PMC: 11680326. DOI: 10.3390/tropicalmed9120307.

Identifying the amino acid domains of ORF59 responsible for interactions with ORF57 and PAN RNA during KSHV lytic replication.

Payen S, Gutierrez I, Andrada K, Verma S, Rossetto C Microbiol Spectr. 2024; :e0116324.

PMID: 39431897 PMC: 11619453. DOI: 10.1128/spectrum.01163-24.

Kaposi sarcoma in an individual recently diagnosed with HIV.

Cronin K, Desai A, Hookim K, Contino G IDCases. 2024; 36:e01961.

PMID: 38699524 PMC: 11063534. DOI: 10.1016/j.idcr.2024.e01961.

References

Jabs D, Van Natta M, Kempen J, Pavan P, Lim J, Murphy R . Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol. 2002; 133(1):48-61. DOI: 10.1016/s0002-9394(01)01322-8. View

Bhutani M, Polizzotto M, Uldrick T, Yarchoan R . Kaposi sarcoma-associated herpesvirus-associated malignancies: epidemiology, pathogenesis, and advances in treatment. Semin Oncol. 2015; 42(2):223-46. PMC: 6309362. DOI: 10.1053/j.seminoncol.2014.12.027. View

Uldrick T, Polizzotto M, Aleman K, Wyvill K, Marshall V, Whitby D . Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. Blood. 2014; 124(24):3544-52. PMC: 4256906. DOI: 10.1182/blood-2014-07-586800. View

Soulier J, GROLLET L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P . Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995; 86(4):1276-80. View

Breton G, Duval X, Estellat C, Poaletti X, Bonnet D, Mvondo Mvondo D . Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis. 2004; 39(11):1709-12. DOI: 10.1086/425742. View

Ratnam I, Chiu C, Kandala N, Easterbrook P . Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis. 2006; 42(3):418-27. DOI: 10.1086/499356. View

Polizzotto M, Uldrick T, Hu D, Yarchoan R . Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV-MCD) and the KSHV Inflammatory Cytokine Syndrome. Front Microbiol. 2012; 3:73. PMC: 3291870. DOI: 10.3389/fmicb.2012.00073. View

Manabe Y, Campbell J, Sydnor E, Moore R . Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr. 2007; 46(4):456-62. DOI: 10.1097/qai.0b013e3181594c8c. View

Uldrick T, Wang V, OMahony D, Aleman K, Wyvill K, Marshall V . An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis. 2010; 51(3):350-8. PMC: 2946207. DOI: 10.1086/654798. View

10.

Brandt S, Bodine D, Dunbar C, Nienhuis A . Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest. 1990; 86(2):592-9. PMC: 296765. DOI: 10.1172/JCI114749. View

11.

Chen Y, Rahemtullah A, Hochberg E . Primary effusion lymphoma. Oncologist. 2007; 12(5):569-76. DOI: 10.1634/theoncologist.12-5-569. View

12.

French M . HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis. 2008; 48(1):101-7. DOI: 10.1086/595006. View

13.

Polizzotto M, Uldrick T, Wyvill K, Aleman K, Marshall V, Wang V . Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS). Clin Infect Dis. 2015; 62(6):730-738. PMC: 4772848. DOI: 10.1093/cid/civ996. View